Headline closes $400M fund, Oura delays IPO, and Fedorov launches Army of Robots

Notable and substantial funding deals were made across Europe this week, totaling over €3.9 billion in investments and 5 exits. In Bilbao, Spain, the BIOSPAIN 2026 event focused on biotech startups, investment, and emerging technologies, as well as broader questions surrounding Europe's competitiveness and strategic autonomy. Meanwhile, in Angers, France, Bull inaugurated a new production facility worth €80 million, expanding its supercomputer and AI infrastructure capabilities by doubling production capacity.

Bull's expansion is part of a broader trend of significant funding rounds. Nscale, an AI cloud pioneer, secured $3.36 billion in pre-IPO financing to fuel its full-stack AI cloud expansion. Reverion, another European player, raised €154 million and plans to hire 800 employees for a new factory. Voi, a Scandinavian micromobility company, secured €150 million in a recent round to redeem outstanding bonds and scale its fleet.

Other noteworthy acquisitions and mergers included the Croatian RPA platform Robotiq.ai being acquired by Indian software giant HCLSoftware, Lottie snapping up CareMaster as part of its AI-driven care operations, and Airbus acquiring French cybersecurity firm Quarkslab.

Investors also made noteworthy moves, with Headline closing a $400 million European fund, DIG Ventures closing $120 million in Fund III to back Europe's AI infrastructure startups, and Sofinnova Partners closing an oversubscribed €82 million fund for Europe's MD Start IV fund. Meanwhile, Blackwall, a Estonian startup, surged 368% in valuation to become the country's newest unicorn.

Meanwhile, Oura delayed its planned $15 billion US IPO, while Mykhailo Fedorov launched an "Army of Robots" initiative to explore using robots in combat instead of human soldiers. Trace.Space introduced Trinity, a new hardware engineering tool designed to address the challenges faced by hardware developers. Berlin-based Apheris and Ginkgo partnered to train AI on 10,000 antibodies for pharmaceutical companies.